---
title: "FOXO TECHNOLOGIES INC | 10-Q: FY2025 Q1 Revenue: USD 3.17 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/241179432.md"
datetime: "2025-05-21T08:12:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/241179432.md)
  - [en](https://longbridge.com/en/news/241179432.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/241179432.md)
---

# FOXO TECHNOLOGIES INC | 10-Q: FY2025 Q1 Revenue: USD 3.17 M

Revenue: As of FY2025 Q1, the actual value is USD 3.17 M.

EPS: As of FY2025 Q1, the actual value is USD -0.37.

### Healthcare Segment

-   **Net Revenues**: $3,161,431 for the three months ended March 31, 2025, compared to $0 for the same period in 2024, due to the acquisition of Myrtle and RCHI.
-   **Operating Expenses**: $4,010,379 for the three months ended March 31, 2025, compared to $0 for the same period in 2024.
-   **Segment Loss**: $844,598 for the three months ended March 31, 2025.

### Labs and Life Segment

-   **Net Revenues**: $8,489 for the three months ended March 31, 2025, compared to $7,180 for the same period in 2024.
-   **Operating Expenses**: $31,494 for the three months ended March 31, 2025, compared to $166,630 for the same period in 2024.
-   **Segment Loss**: $23,005 for the three months ended March 31, 2025, compared to $159,450 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: $1,337,591 for the three months ended March 31, 2025, compared to $406,302 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $1,286,230 for the three months ended March 31, 2025, compared to $370,720 for the same period in 2024.

### Future Outlook and Strategy

-   **Healthcare Segment**: The company plans to expand the Myrtle business model by acquiring additional operating facilities and replicating the model in other rural hospital properties or suitable premises.
-   **Labs and Life Segment**: The company is focusing on its Bioinformatics Services offering and research and development in health and wellness testing powered by machine learning and artificial intelligence.

### Strategic Initiatives

-   **Reverse Stock Split**: Implemented a 1-for-10 reverse stock split effective April 28, 2025.
-   **Amended and Restated Strata Purchase Agreement**: Extended the maturity date to June 30, 2026, and improved the purchase price definition.

### Risks and Challenges

-   The company faces substantial doubt about its ability to continue as a going concern due to insufficient capital to fund operations for at least 12 months.

### Related Stocks

- [FOXOW.US](https://longbridge.com/en/quote/FOXOW.US.md)

## Related News & Research

- [FACTBOX-IPO-bound SpaceX's board is stacked with Musk empire loyalists](https://longbridge.com/en/news/287206089.md)
- [INSTANT VIEW-SpaceX files long awaited IPO, creating a fresh AI play](https://longbridge.com/en/news/287124128.md)
- [ANALYSIS-Why SpaceX's mega IPO may not signal a broader rebound in listings](https://longbridge.com/en/news/287215490.md)
- [GRAPHIC-Major takeaways from Magnificent Seven's AI-fueled earnings](https://longbridge.com/en/news/287224928.md)
- [SanDisk (SNDK) Has Surprised Me. I'm Still Not Buying the Stock Yet](https://longbridge.com/en/news/287177163.md)